IOVA vs URGN: which is the better buy in 2026?
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
First approved solid tumor cell therapy with a real commercial ramp, priced like it's still pre-revenue. The setup is asymmetric.
Full IOVA analysisUroGen Pharma Ltd.
NASDAQ:URGN
Zusduri is rewriting how urologists treat bladder cancer, and the early script data is louder than the share price suggests.
Full URGN analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is IOVA or URGN the better buy in 2026?
IOVA and URGN are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.
How does Alexandria compare IOVA and URGN?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.